Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
² Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
³ Department of Chest Medicine, Masan National Tuberculosis Hospital, Masan, Republic of Korea.
⁴ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

C Chung et al. Int J Tuberc Lung Dis. 2023.

. 2023 Feb 1;27(2):151-153.

doi: 10.5588/ijtld.22.0466.

¹ Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
² Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
³ Department of Chest Medicine, Masan National Tuberculosis Hospital, Masan, Republic of Korea.
⁴ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

No abstract available

Comment in

Bedaquiline-based all-oral regimen for macrolide-resistant Mycobacterium abscessus pulmonary disease.
Riccardi N, Occhineri S, Matucci T, Marchetti G, Rindi L, Tiseo G, Cirillo DM, Falcone M. Riccardi N, et al. Int J Tuberc Lung Dis. 2023 Sep 1;27(9):712-713. doi: 10.5588/ijtld.23.0220. Int J Tuberc Lung Dis. 2023. PMID: 37608476 Free PMC article. No abstract available.